Suppliers and packagers for DEFINITY

Definity is supplied in the U.S. as perflutren lipid microsphere for echocardiography. It is commercially sourced from the branded product supply chain and is subject to distribution controls tied to FDA labeling, lot release, and controlled cold-chain handling requirements.

Who supplies Definity (perflutren lipid microsphere) in the U.S.?

Answer: Definity is marketed and supplied under the branded product supply chain in the U.S.; U.S. distribution is tied to the FDA-licensed product and its labeled manufacturing and release system. The supplier set is defined by the marketing authorization holder’s distribution network and any contracted manufacturers used for drug substance and drug product manufacturing and sterile fill-finish.

What entities typically appear in the Definity supply chain

For injectable sterile suspensions like Definity, supply roles usually split into:

• Marketing authorization holder and U.S. distributor of record
• Contract manufacturers for sterile drug product fill-finish (and any contract packaging)
• Sterile filtration, aseptic processing and lot release testing sites
• Logistics and cold-chain distribution partners responsible for temperature-controlled shipment

What “supplier” means for Definity

In contrast products, “supplier” usually maps to one of three procurement targets:

1. Branded product distributor of record (what hospitals buy)
2. Contract manufacturing sites (where production occurs)
3. Component suppliers (lipid components, perflutren-related constituents, vials, closures)

Which manufacturers make Definity (perflutren lipid microsphere) drug product and sterile fill-finish?

Answer: Definity’s drug product is produced as a sterile injectable suspension using a commercial manufacturing and aseptic fill-finish process that is approved as part of the NDA labeling and manufacturing section controls.

Key manufacturing inputs that constrain sourcing

• Sterile fill-finish capacity for vial-based lipid microsphere suspensions
• Raw material availability for lipid components used to form the microsphere shell
• Aseptic processing and validated sterile manufacturing environment
• Lot release testing capacity (microbial limits, particle characteristics, potency/quality attributes)

What are the Definity component suppliers (lipids, vials, closures) in the supply chain?

Answer: Definity’s component sourcing is controlled through approved raw-material specifications and vendor qualification programs. Component suppliers are contract-qualified and managed by the marketing authorization holder or its manufacturing partners, and raw materials are not typically exposed as public “approved alternative sources” in the same way as finished-goods suppliers.

Components that typically require qualified suppliers

• Lipid constituents for the microsphere formulation
• Buffer and stabilizers used in the suspension
• Sterile vial, stopper (elastomer selection), and seal systems
• Packaging and labeling components tied to U.S. labeling requirements
• Contract logistics providers for temperature-controlled delivery

Which companies supply generic or biosimilar equivalents of Definity?

Answer: Definity is a small-molecule contrast product, and “generic equivalents” in practice map to FDA-approved ANDA products or unapproved imports depending on regulatory posture. Whether any FDA-approved generic equivalents exist depends on the Orange Book status and FDA approval history for perflutren lipid microsphere products.

What to check to identify generic-equivalent suppliers

• FDA “Orange Book” listings for perflutren lipid microsphere products
• Approval records for any ANDAs referencing Definity
• Labeling equivalence and strength/dosage form matching (vial-based injectable suspension)

What does the Orange Book status of Definity imply for supply competition?

Answer: Orange Book listings define whether competing applicants (ANDAs) have a legally exploitable pathway and whether supply competition exists. If the branded product is protected by active exclusivities and unexpired patents, the competitive supplier pool is generally constrained to the brand supply chain.

How exclusivity and patents affect supplier availability

• Active patents can limit ANDA launch timing and thus restrict supplier competition
• Exclusivity periods can delay entry of alternative manufacturers
• Any approved “fallback” exclusivity can shift when competition appears

How does Definity’s distribution model affect hospital procurement and supplier switching?

Answer: Distribution is controlled through FDA-lot release and cold-chain logistics. That means switching suppliers in procurement is usually a function of finished-goods availability (brand lots) rather than rapid interchange of contract manufacturing sites.

Operational procurement constraints

• Lot-level release schedules and lead times
• Temperature handling requirements from manufacturer to wholesaler
• Hospital formulary contracting that locks in SKU and distribution terms

What generic entry risks exist for Definity (perflutren lipid microsphere)?

Answer: Entry risk is driven by patent and exclusivity expiration, plus the feasibility of sterile microsphere manufacturing at scale. When barriers remain active, risk is low for near-term supply diversification.

Manufacturing and regulatory barriers that affect entry timing

• Aseptic sterile manufacturing validation
• Consistent microsphere size distribution and stability
• Analytical method transfer and bridging studies (where applicable)
• Stability data and shipping-conditions validation for vials

How does Definity compare on supply-chain stability vs other echocardiography contrast agents?

Answer: Like other injectable contrast agents, Definity’s supply stability depends on sterile manufacturing capacity, component supply, and lot release testing throughput. Product-specific factors include the microsphere formulation process and vial configuration.

Common contrast-agent supply failure modes

• Sterile manufacturing downtime
• Raw material shortages affecting batch-release attributes
• Cold-chain carrier disruptions

What patent estate controls Definity supply and manufacturer switching?

Answer: Definity supply is controlled primarily through patent and exclusivity protections covering perflutren lipid microsphere composition, manufacturing processes, and/or approved use. When those protections are active, competing suppliers are constrained.

What patent categories typically constrain entrants

• Composition-of-matter around lipid microsphere formulation
• Method-of-manufacture processes for microsphere generation and sterilization
• Method-of-use or labeling-linked claims for echocardiography contrast use

Key Takeaways

• Definity supply is dominated by the branded product supply chain, with distribution governed by FDA-lot release, sterile manufacturing controls, and logistics constraints.
• “Suppliers” in procurement typically mean the distributor of record and any contract manufacturing and logistics providers validated under the NDA framework.
• Supplier switching is usually limited to finished-goods availability until patent and exclusivity barriers for perflutren lipid microsphere equivalents are cleared.

FAQs

1. Is Definity supplied only by the brand manufacturer, or are there alternative distributors?
   Supply runs through the branded distribution chain tied to FDA lot release and cold-chain logistics; alternative distributors typically act as channel partners rather than alternate product sources.

2. Are there generic equivalents to Definity that hospitals can procure from multiple FDA-approved suppliers?
   Availability depends on FDA-approved ANDA competition and the Orange Book/patent status for perflutren lipid microsphere.

3. Who controls cold-chain logistics for Definity shipments to wholesalers and hospitals?
   Logistics handling is managed by the product’s distribution network and contracted carriers qualified for temperature-controlled delivery.

4. What manufacturing steps make Definity hard to replicate for new entrants?
   Aseptic fill-finish, microsphere formulation consistency, and batch release testing for defined quality attributes.

5. How do patent expirations affect future Definity supplier diversification?
   Once protected periods lapse, ANDA applicants can launch, expanding the set of FDA-approved finished-goods suppliers.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA database).
2. U.S. Food and Drug Administration. Drug Approval Reports and NDA/ANDA records for perflutren lipid microsphere products (Definity reference product and any ANDAs). (FDA databases).
3. FDA Labeling for Definity (perflutren lipid microsphere) prescribing information. (FDA access).